Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 16, 2023, the Board of Directors (the "Board") of Medpace Holdings, Inc. (the "Company"), following a recommendation from the independent directors of the Board, unanimously approved that Dr. Femida H. Gwadry-Sridhar be elected to fill the Class I director vacancy on the Board of the Company, effective January 16, 2023, and that Dr. Gwadry-Sridhar shall hold such position as a Class I director until the 2023 Annual Meeting of Stockholders and until her successor is duly elected and qualified or until her earlier death, resignation or removal. Dr. Gwadry-Sridhar is expected to be appointed to the Nominating and Governance Committee.

Dr. Gwadry-Sridhar is the Founder and Chief Executive Officer of Pulse Infoframe Inc, a privately held real-world evidence generation platform company providing solutions for disease registries, natural history studies and other observational and regulatory grade studies since 2011. During her career she has held academic appointments at Western University and as a visiting Professor at the University of Southern California. Dr. Gwadry-Sridhar is considered a thought leader in real-world evidence with over 220 publications in top tier journals, recognition as a career scientist and lifetime fellow of the Canadian Institute of Health Research (CIHR), and as a founding member of the medical adherence group at the Society for Pharmacoeconomics and Outcomes Research (ISPOR). She has been recognized as and supports female entrepreneurs in digital health and has served on numerous community and non-profit boards. She is also a Director of Pulse Infoframe Inc. and Pulse Infoframe US, LLC.

Dr. Gwadry-Sridhar received a B.S. Biology from Western University, a B.Sc.Phm. from University of Toronto, a M.Sc. (epi) from Western University and Ph.D. in health research methodology from McMaster University.

Dr. Gwadry-Sridhar will participate in the Company's standard compensation program for non-employee directors. On January 16, 2023, Dr. Gwadry-Sridhar was granted an equity award in the form of an option to purchase 573 shares of the Company's common stock with an exercise price equal to the closing price per share of the Company's common stock on January 13, 2023, the last preceding trading day because the date of Dr. Gwadry-Sridhar's election was not a trading day, and a term of seven years. The Company has entered into the Company's standard indemnification agreement for directors and officers with Dr. Gwadry-Sridhar.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses